

Clinical Policy: Lung Transplantation

Reference Number: CP.MP.57 [Coding Implications](#_bookmark0) Last Review Date: 05/20 [Revision Log](#_bookmark1)

# See [Important Reminder](#_bookmark2) at the end of this policy for important regulatory and legal information.

**Description**

Medical necessity criteria for the review of lung transplantation requests.

# Policy/Criteria

1. It is the policy of health plans affiliated with Centene Corporation® that lung transplant for members with chronic, end-stage lung disease who have failed maximal medical therapy is **medically necessary** when all of the following criteria are met:
	1. High (> 50%) risk of death from lung disease within 2 years if lung transplantation is not performed.
	2. High (> 80%) likelihood of surviving at least 90 days after lung transplantation.
	3. High (> 80%) likelihood of 5-year post-transplant survival from a general medical perspective provided that there is adequate graft function.
	4. Does not have ANY of the following absolute contraindications:
		1. Malignancy, except for non-melanoma localized skin cancer that has been treated appropriately, low grade prostate cancer, a malignancy that has been completely resected, or a treated malignancy determined to have a small likelihood of recurrence and acceptable future risks;
		2. Untreatable significant dysfunction of another major organ system unless combined organ transplantation can be performed;
		3. Uncorrected atherosclerotic disease with suspected or confirmed end-organ ischemia or dysfunction and/or coronary artery disease not amenable to revascularization;
		4. Acute medical instability, including, but not limited to, acute sepsis, acute viral respiratory infection, myocardial infarction, and liver failure;
		5. Uncorrectable bleeding diathesis;
		6. Chronic infection with highly virulent and/or resistant microbes that are poorly controlled pre-transplant;
		7. Evidence of active *Mycobacterium tuberculosis* infection and/or smear-positive non- tuberculous mycobacterial infection;
		8. Significant chest wall/spinal deformity expected to cause severe restriction after transplantation;
		9. Class II or III obesity (body mass index ≥ 35.0 kg/m2);
		10. Current non-adherence to medical therapy or a history of repeated or prolonged episodes of non-adherence to medical therapy that are perceived to increase the risk of non-adherence after transplantation;
		11. Psychiatric or psychological condition associated with the inability to cooperate or comply with medical therapy;
		12. Absence of an adequate or reliable social support system;
		13. Severely limited functional status with poor rehabilitation potential;
		14. Substance abuse or dependence (including tobacco and alcohol) without appropriate risk reduction behaviors, such as meaningful and/or long-term participation in therapy for substance abuse and/or dependence;
			1. Documentation of abstinence from smoking for 6 months before consideration to be eligible for transplant.
	5. Has one of the following disease states and meets its corresponding criteria (not an all- inclusive list):
		1. *Adult members, age ≥ 18:*
			1. Interstitial lung disease and any of the following:
				1. Decline in forced vital capacity (FVC) ≥ 10% during 6 months of follow-up (note: a 5% decline is associated with a poorer prognosis and may warrant listing);
				2. Decline in diffusing capacity of the lung for carbon monoxide (DLCO ) ≥15% during 6 months of follow-up;
				3. Desaturation to < 88% or distance < 250 m on 6-minute-walk test (6MWT) or

> 50 m decline in 6MWT distance over a 6-month period;

* + - * 1. Pulmonary hypertension on right heart catheterization or 2-dimensional echocardiography;
				2. Hospitalization because of respiratory decline, pneumothorax, or acute exacerbation;
			1. Cystic fibrosis (CF) or other causes of bronchiectasis, and any of the following:
				1. Chronic respiratory failure and one of the following:

With hypoxia alone (partial pressure of oxygen [PaO2] < 8 kPa or < 60 mm Hg);

With hypercapnia (partial pressure of carbon dioxide [PaCO2] > 6.6 kPa or

> 50 mmHg);

* + - * 1. Long-term non-invasive ventilation therapy;
				2. Pulmonary hypertension;
				3. Frequent hospitalization with a clinical trajectory of worsening quality of life and lung function;
				4. Rapid lung function decline;
				5. World Health Organization (WHO) Functional Class IV.
			1. Chronic obstructive pulmonary disease (COPD), and any of the following:
				1. BODE index (includes BMI, degree of airflow obstruction, degree of dyspnea, and exercise capacity) ≥ 7;
				2. FEV1 (forced expiratory volume in 1 second) < 15 to 20% of predicted;
				3. Three or more severe exacerbations during the preceding year;
				4. At least one severe exacerbation with acute hypercapnic respiratory failure;
				5. Moderate to severe pulmonary hypertension;
			2. Pulmonary vascular diseases and any of the following:
				1. New York Heart Association (NYHA) Functional Class III or IV despite a trial of at least 3 months of combination therapy including prostanoids;
				2. Cardiac index of < 2 liters/min/m2;
				3. Mean right atrial pressure > 15 mm Hg;
				4. 6MWT of < 350 m;
				5. Development of significant hemoptysis, pericardial effusion, or signs of progressive right heart failure (renal insufficiency, increasing bilirubin, brain natriuretic peptide, or recurrent ascites);
			3. Eisenmenger syndrome with pulmonary hypertension despite therapy aimed at avoiding polycythemia, iron deficiency and dehydration, and the associated profound hypoxemia and impaired quality of life;
			4. Lymphangioleiomyomatosis and any of the following:
				1. Severe impairment in lung function and exercise capacity (e.g., VO2 max

<50% predicted);

* + - * 1. Hypoxemia at rest;
			1. Primary lung graft failure or bronchiolitis obliterans.
		1. *Pediatric members, age < 18:*
			1. Cystic fibrosis, and any of the following:
				1. Progressive lung disease and disability despite optimal medical therapy;
				2. FEV1 < 30%;
				3. Increasingly frequent hospitalizations;
				4. Hypoxemia, ( PaO2 < 8 kPa or < 60 mm Hg);
				5. Hypercapnia, (PaCO2 > 6.6 kPa or > 50 mmHg);
			2. Idiopathic pulmonary arterial hypertension, and any of the following:
				1. NYHA or WHO functional class III or IV despite vasodilator therapy;
				2. Low exercise tolerance with 6MWT < 350 meters;
				3. Uncontrolled syncope;
				4. Hemoptysis;
				5. Right-sided heart failure;
				6. Failure to respond to vasodilator therapy;
			3. Pulmonary vascular disease and failure to respond to medical management;
			4. Eisenmenger syndrome with pulmonary hypertension despite therapy aimed at avoiding polycythemia, iron deficiency and dehydration, and the associated profound hypoxemia and impaired quality of life;
			5. Surfactant dysfunction disorders with unrelenting respiratory failure, or progressive interstitial lung disease with respiratory insufficiency, unresponsive to medical interventions;
			6. Bronchopulmonary dysplasia, and any of the following:
				1. Extended time requiring ventilator support without clinical improvement;
				2. Pulmonary hypertension unresponsive to oxygen therapy;
				3. Repeated episodes of respiratory failure without improvement in clinical trajectory over time, despite good medical support;
				4. Progressive pulmonary hypertension;
			7. Diffuse parenchymal lung disease, and any of the following:
				1. Disease progression despite optimal management;
				2. Poor quality of life;
			8. Primary lung graft failure or bronchiolitis obliterans.

# Background

Lung transplantation is an accepted therapy for the management of a range of severe lung disorders. Single, double, and lobar-lung transplants have all been successful for carefully selected patients with end-stage pulmonary disease. The most common disease processes for which lung transplants are performed include COPD, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, and sarcoidosis.

COPD is one of the most common lung diseases and is the most common indication for lung transplantation. Chronic bronchitis and emphysema are the two main forms of COPD, both most commonly caused from smoking. Non-smokers with an alpha-1 antitrypsin deficiency can also develop emphysema. These conditions are the most common indications for single lung transplants. Cystic fibrosis, emphysema, and alpha-1 antitrypsin deficiency are the most common indications for double lung transplant, or sequential replacement of both lungs.

The most common indications for pediatric lung transplants include pulmonary vascular disease, bronchiolitis obliterans, bronchopulmonary dysplasia, graft failure due to viral pneumonitis, and CF.

# Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2019, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage.

Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| **CPT®****Codes** | **Description** |
| --- | --- |
| 32851 | Lung transplant, single; without cardiopulmonary bypass |
| 32852 | Lung transplant, single; with cardiopulmonary bypass |
| 32853 | Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass |
| 32854 | Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass |

| **HCPCS****Codes** | **Description** |
| --- | --- |
| S2060 | Lobar lung transplantation |
| S2152 | Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor (s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and post-transplant care in the global definition |

# ICD-10-CM Diagnosis Codes that Support Coverage Criteria

| **ICD-10-CM****Code** | **Description** |
| --- | --- |
| C96.6 | Unifocal Langerhans-cell histiocytosis  |
| D86.0 | Sarcoidosis of lung |
| E84.0-E84.9 | Cystic fibrosis |
| E88.01 | Alpha-1-antitrypsin deficiency |
| I27.0 | Primary pulmonary hypertension |
| I27.23 | Pulmonary hypertension due to lung diseases and hypoxia |
| I27.83 | Eisenmenger's syndrome |
| I27.89 | Other specified pulmonary heart disease |
| I27.9 | Pulmonary heart disease, unspecified disease,unspecified |
| J41.8 | Mixed simple and mucopurulent chronic bronchitis |
| J42 | Unspecified chronic bronchitis |
| J43.0-J43.9 | Emphysema |
| J44.0-J44.9 | Other chronic obstructive pulmonary disease |
| J47.0-J47.9 | Bronchiectasis |
| J60 | Coal worker’s Pneumoconiosisworker’sPneumoconiosis |
| J61 | Pneumoconiosis due to asbestos and other mineral fibers |
| J62.0-J62.8 | Pneumoconiosis due to dust containing silica silica |
| J63.0-J63.6 | Pneumoconiosis due to other inorganic dusts |
| J84.10 | Pulmonary fibrosis, unspecified |
| J84.111-J84.17 | Idiopathic interstitial pneumonia |
| J84.81 | Lymphangioleiomyomatosis |
| J84.82 | Adult pulmonary Langerhans cell histiocytosis |
| J84.83 | Surfactant mutations of the lung |
| J84.89  | Other specified interstitial pulmonary disease e |
| J98.2 | Interstitial emphesema |
| J99 | Respiratory disorders in diseases classified elsewheredisordersindiseasesclassifiedelsewhere |
| P27.0-P27.9 | Chronic respiratory disease originating in the perinatal periodoriginatingintheperinatal period |
| Q21.8 | Other congenital malformations of cardiac septacongenitalmalformationsofcardiac septa |
| Q33.0-Q33.9 | Congenital malformations of the lungmalformations of the lung |
| T86.810-T86.819 | Complications of lung transplant |
| Z99.89 | Dependence on other enabling machines and devicesand devices |

| **Reviews, Revisions, and Approvals** | **Date** | **Approval****Date** |
| --- | --- | --- |
|  Policy developed Specialist review | 01/14 | 02/14 |
|  References reviewed and updatedreviewedandupdated | 02/15 | 02/15 |
|  Converted into new policy template, references reviewed and updated | 02/16 |  |
| Updated criteria to match 2014 International Guidelines for the Selection ofLung Transplant Candidates: updated likelihood of survival and absolute contraindications; updated cystic fibrosis criteria; updated COPD criteria; combined diseases together that classify as interstitial lung disease; updated PAH to pulmonary vascular diseases and associated criteria. | 03/16 | 03/16 |
| Added pediatric specific criteria. Added “acute viral respiratory infection” to I.D.4. and “and/or smear-positive non-tuberculous mycobacterial infection” to I.D.7. Added “with a clinical trajectory of worsening quality of life and lung function” to adult cystic fibrosis criteria for frequent hospitalization. Removed background regarding lobar-lung transplant.Added HCPCS and ICD-10 code tables. Reviewed by external pediatric pulmonologist.  | 10/16 | 11/16 |
| Added Eisenmenger syndrome as a qualifying condition for adult transplant. Added that the list of qualifying conditions for transplant is not all-inclusive. Added primary lung graft failure and bronchiolitis obliterans as an indication for adult and pediatric transplant since ISHLT guidelines recommend retransplant in certain cases. Updated coding. Added time frame for which smoking cessation should be documented. | 11/17 | 11/17 |
| In criteria pertaining to substance use, removed the statement that serial blood and urine testing” may be required, as it is informational only. In the adult COPD criteria, changed “one severe exacerbation” to “at least one severe exacerbation.” | 06/18 |  |
| References reviewed and updated.  | 10/18 | 10/18 |
| References reviewed and updated. Specialist review | 08/19 | 09/19 |
| Edited malignancy contraindication to not specify within 2 years, and added exceptions of early stage prostate cancer, cancer that has been completely resected, or that has been treated and poses acceptable future risk. | 05/20 | 05/20 |

**References**

1. A.D.A.M. Medical Encyclopedia [Internet]. Chronic obstructive pulmonary disease. PubMed Health. National Library of Medicine, National Institutes of Health. Updated November 6, 2017.
2. Bischel MD. Medical review criteria guidelines for managed care: lung (pulmonary) transplantation. Apollo Managed Care Inc. Twelveth Edition, 2013.
3. Biswas RS, Panchanathan R, Walia R, et al. Lung retransplantation for chronic refection: A single-center experience. Ann Thorac Surg. 2017 Nov 1. pii: S0003-4975(17)31050-0. doi: 10.1016/j.athoracsur.2017.07.025.
4. Christie JD, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Lung and Heart-Lung Transplant Report--2011. Journal of Heart and Lung Transplantation 2011;30(10):1104-22.
5. Faro A, Mallory GB, Visner GA, et al. American Society of Transplantation executive summary on pediatric lung transplantation. Am J Transplant. 2007 Feb;7(2):285-92. Epub 2006 Nov 15.
6. Goldfarb SB, et al. "The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report- 2015; Focus Theme: Early Graft Failure." The Journal of heart and lung transplantation: the official publication of the International Society for Heart Transplantation 34.10 (2015): 1255.
7. Hachem RR. Lung transplantation: An overview. In: UpToDate, Trulock EP (Ed), UpToDate, Waltham, MA. Accessed on 08/29/19.
8. Hachem RR. Lung transplantation: Disease-based choice of procedure. In: UpToDate, Trulock EP (Ed), UpToDate, Waltham, MA. Accessed on 08/130/19.
9. Hachem RR. Lung transplantation: General guidelines for recipient selection. In: UpToDate, Trulock EP (Ed), UpToDate, Waltham, MA. Accessed on 08/30/19.
10. Hall DJ, Belli EV, Gregg JA, et al. Two decades of lung retransplantation: a single-center experience. Ann Thorac Surg. 2017 Apr;103(4):1076-1083. doi: 10.1016/j.athoracsur.2016.09.107.
11. Kirkby, Stephen, and Don Hayes Jr. "Pediatric lung transplantation: indications and outcomes." *Journal of thoracic disease* 6.8 (2014): 1024-1031.
12. Kotloff RM, Thabut G. Lung transplantation. American Journal of Respiratory and Critical Care Medicine 2011;184(2):159-71. Available at: <https://www.atsjournals.org/doi/full/10.1164/rccm.201101-0134CI?prevSearch=lung%2Btransplantation&amp;searchHistoryKey=&>
13. Meyer KC. Lung transplantation. F1000Prime Reports 2013, 5:16 (doi:10.12703/P5-16).
14. Moffat-Bruce SD, et al. Lung Transplantation. Medscape Reference. Updated 4/8/17. [http://emedicine.medscape.com/article/429499-overview.](http://emedicine.medscape.com/article/429499-overview)
15. National Institute for Health and Clinical Excellence. Living-donor lung transplantation for end-stage lung disease. May 2006. <http://www.nice.org.uk/nicemedia/pdf/IPG170guidance.pdf>
16. Organ Procurement and Transplantation Network. Policies effective 9/1/2018. <https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf>
17. Weil D, Benden C, Corris PA et al. A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. *The Journal of Heart and Lung Transplantation*, January 2015; 34(1) 1-15. <http://dx.doi.org/10.1016/j.healun.2014.06.014>

# Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note: For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members,** to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at [http://www.cms.gov](http://www.cms.gov/) for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.